NCT02482532View on ClinicalTrials.gov

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

October 10, 2019

Study Completion Date

September 13, 2021

Conditions
Melanoma
Interventions
BIOLOGICAL

tvs-CTL Vaccine

autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)

Trial Locations (1)

66205

KU Cancer Center, Fairway

All Listed Sponsors
lead

Gary Doolittle

OTHER

NCT02482532 - Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma | Biotech Hunter | Biotech Hunter